Literature DB >> 18059221

Prognostic features of surgical stage I uterine carcinosarcoma.

Sarah E Ferguson1, Carmen Tornos, Amanda Hummer, Richard R Barakat, Robert A Soslow.   

Abstract

Uterine carcinosarcomas (CSs) are aggressive neoplasms, with 5-year overall survival (OS) rates of less than 35%. They are customarily separated into types harboring either heterologous or homologous mesenchymal elements, but the prognostic significance of this finding is controversial. Our goal was to study clinicopathologic features of possible prognostic relevance in surgical stage I uterine CS. A retrospective clinical and histopathologic review was performed for all women diagnosed with surgical stage I uterine CS. These tumors were compared with stage I high-grade endometrial (HGEm) carcinomas for clinical outcomes. There were 42 cases of surgical stage I uterine CS identified between January 1990 and January 2004. The disease-free survival and OS rates for patients with stage I CS were significantly worse compared with stage I HGEm (P=0.001; P=0.01). The median disease-free survival for patients with heterologous CS was 15 months and had not been reached for women with homologous CS (P=0.001). The 3-year OS rates were 45% versus 93% in women with heterologous compared with homologous stage I CS (P<0.001). The 3-year OS rates for homologous CS and HGEm were both >90%. Homologous stage I CSs have survival outcomes that are similar to HGEm. This further supports the concept that homologous stage I CSs are carcinomas with sarcomatoid features, not sarcomas. More importantly, the presence of heterologous sarcomatous elements is a powerful negative prognostic factor in surgical stage I uterine CS.

Entities:  

Mesh:

Year:  2007        PMID: 18059221     DOI: 10.1097/PAS.0b013e3181161ba3

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  28 in total

1.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

Review 2.  [New features in the 2014 WHO classification of uterine neoplasms].

Authors:  S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

3.  Laparoscopic management of uncommon benign uterine tumors: a systematic review.

Authors:  Zaki Sleiman; Sara Hussein; Amani Mohsen; Aline Khazzaka; Alessandro Tropea; Antonio Biondi
Journal:  Updates Surg       Date:  2019-04-02

4.  Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.

Authors:  Koji Matsuo; Kohei Omatsu; Malcolm S Ross; Marian S Johnson; Mayu Yunokawa; Merieme M Klobocista; Dwight D Im; Stephen H Bush; Yutaka Ueda; Tadao Takano; Erin A Blake; Kosei Hasegawa; Tsukasa Baba; Masako Shida; Shinya Satoh; Takuhei Yokoyama; Hiroko Machida; Sosuke Adachi; Yuji Ikeda; Keita Iwasaki; Takahito M Miyake; Shiori Yanai; Masato Nishimura; Tadayoshi Nagano; Munetaka Takekuma; Satoshi Takeuchi; Tanja Pejovic; Mian Mk Shahzad; Frederick R Ueland; Joseph L Kelley; Lynda D Roman
Journal:  Gynecol Oncol       Date:  2017-02-16       Impact factor: 5.482

5.  Prognostic factors impacting survival in early stage uterine carcinosarcoma.

Authors:  Katherine C Kurnit; Rebecca A Previs; Pamela T Soliman; Shannon N Westin; Ann H Klopp; Bryan M Fellman; Karen H Lu; Lois M Ramondetta; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2018-11-08       Impact factor: 5.482

6.  Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.

Authors:  Hiroshi Yoshida; Tadaaki Nishikawa; Koji Matsumoto; Masahiko Mori; Yasuyuki Hirashima; Kazuhiro Takehara; Kazuya Ariyoshi; Kosei Hasegawa; Kan Yonemori
Journal:  Virchows Arch       Date:  2021-01-09       Impact factor: 4.064

7.  Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.

Authors:  Lei Zhang; David Shimizu; Jeffrey L Killeen; Stacey A Honda; Di Lu; Alexander Stanoyevitch; Fritz Lin; Beverly Wang; Edwin S Monuki; Michele Carbone
Journal:  Hum Pathol       Date:  2016-03-11       Impact factor: 3.466

Review 8.  A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus.

Authors:  W Glenn McCluggage
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

Review 9.  Review of Recommended Treatment of Uterine Carcinosarcoma.

Authors:  Joseph Menczer
Journal:  Curr Treat Options Oncol       Date:  2015-11

10.  Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.

Authors:  Xiaofan Lu; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Xiao Lin; Yue Wang; Qianyuan Zhang; Tao Lu; Fangrong Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.